PharVision Advisers’s Cameco CCJ Stock Holding History

PharVision Advisers’s Portfolio CCJ Stock Details CCJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,542	Closed	-$233K	–	191
2025 Q4	$233K	Buy	+2,542	New	+$229K	0.12%	434

Other funds holding CCJ

Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $73.7B AUM 53.56% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

PharVision Advisers's CCJ Position: Q1 2026 in Review

PharVision Advisers sold out of Cameco (CCJ) in Q1 2026, closing a stake of 2,542 shares — an estimated $233K sold.

PharVision Advisers first reported a position in CCJ in Q4 2025 and held it in 1 quarter. The position peaked at $233K in Q4 2025. 1,015 funds tracked by Wall St. Rank hold CCJ as of Q1 2026.

PharVision Advisers reported no remaining Cameco position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 2,542 Cameco shares in Q1 2026, an estimated $233K.
PharVision Advisers first reported a position in Cameco in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Cameco position peaked at $233K in Q4 2025.
1,015 funds tracked by Wall St. Rank held Cameco as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.